NCT02981628 2026-02-23
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 2 Recruiting
Clinical Trials
11 trialsNCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
NCT02877303 2025-11-06
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05303792 2025-04-02
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT06754267 2024-12-31
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06742515 2024-12-19
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06554626 2024-08-15
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT00849147 2023-01-04
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Medical College of Wisconsin
Phase 2 Completed
NCT00864227 2022-12-14
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
Medical College of Wisconsin
Phase 2 Completed
NCT03321123 2017-10-25
MB-CART19.1 in Patients With R/R ALL
Shanghai Children's Medical Center
Phase 2 Unknown
NCT01116193 2017-09-14
RV-405 LAL
Institut de Cancérologie de la Loire
Phase 2 Completed